Capricor Therapeutics

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Our mission is to create innovative and transformative cardiovascular therapeutics that will improve the lives of patients worldwide.

Our vision is to be a leader in the development of novel therapeutics to treat cardiovascular diseases.

Capricor has received numerous awards and recognitions for its contributions to the cardiovascular field, including the “Most Innovative Cardiology Product” award from the International Journal of Medical Sciences, the “Best Cardiac Therapy” award from the American Society of Medical Research, and the “Excellence in Research” award from the American Heart Association.